136 related articles for article (PubMed ID: 37714979)
1. Melanin-targeted [
Zhang X; Kang F; Zheng H; Gai Y; Wang J; Lan X
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):196-201. PubMed ID: 37714979
[TBL] [Abstract][Full Text] [Related]
2.
Zhang X; Li M; Gai Y; Chen J; Tao J; Yang L; Hu F; Song W; Yen TC; Lan X
J Nucl Med; 2022 Oct; 63(10):1537-1543. PubMed ID: 35115367
[No Abstract] [Full Text] [Related]
3. Melanin-targeted [
Zhang X; Lin Z; Li M; Gai Y; Zheng H; Fan L; Ruan W; Hu F; Chen J; Lan X
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3062-3071. PubMed ID: 37191681
[TBL] [Abstract][Full Text] [Related]
4. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
[TBL] [Abstract][Full Text] [Related]
5. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
7. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
9. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
11. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
12. Melanin-Targeted PET Imaging Sheds Light on Pigment Epithelioma in Corpus Ciliare.
Zhang X; Li M; Hu F; Lan X
Clin Nucl Med; 2022 Sep; 47(9):839-840. PubMed ID: 35930712
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma.
Liu DD; Li J; Li X; Xie L; Qin L; Peng F; Cheng MH
J Gynecol Oncol; 2019 Nov; 30(6):e89. PubMed ID: 31576685
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. The role of
Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206
[TBL] [Abstract][Full Text] [Related]
16. Correlation between
Zhao J; Wang H
J Med Imaging Radiat Oncol; 2021 Apr; 65(2):188-194. PubMed ID: 33538120
[TBL] [Abstract][Full Text] [Related]
17. Lymph node standardized uptake values at pre-treatment
Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
[TBL] [Abstract][Full Text] [Related]
18. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
19.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
